#United States #San Diego #Atrium Therapeutics #PRKAG2 Syndrome #ATR 1072

Atrium Therapeutics Reports Financial Results and Clinical Progress in Q3 2026

Atrium Therapeutics, a pioneering biopharmaceutical firm committed to transforming cardiology through RNA therapeutics, has announced strong financial results for the third quarter of 2026. The company reported notable developments, particularly with its innovative drug, ATR 1072, aimed at treating PRKAG2 syndrome, a rare genetic cardiomyopathy.

Financial Highlights

In the latest earnings report, Atrium disclosed a pro forma cash balance of $293.6 million as of September 30, 2026, which is expected to sustain operations through 2028. The increased cash flow is attributed to a successful $50 million private placement, aiding the company in its clinical pursuits. Overall, collaboration revenue for the quarter stood at $15.3 million, largely driven by a milestone payment from their partnership with Bristol Myers Squibb (BMS).

Key Financial Indicators

• - Collaboration Revenue: $15.3 million
• - Research and Development Expenses: $13.8 million
• - General and Administrative Expenses: $8.2 million
• - Net Loss: $4.3 million

Clinical Milestones

A significant highlight for Atrium has been the initiation of the Corventis Phase 1/2 clinical trial, treating patients with PRKAG2 syndrome with ATR 1072. This trial marks a groundbreaking effort, as it is the first to address the genetic root of the condition. Early nonclinical data revealed promising results where ATR 1072 effectively reversed cardiac glycogen accumulation—an underlying issue in PRKAG2 syndrome.

The trial aims to evaluate the safety, tolerability, and efficacy of ATR 1072 in participants, reinforcing Atrium's commitment to advancing precision cardiology. Kathleen Gallagher, President and CEO of Atrium, emphasized that the past eight months have been pivotal in transitioning the company to a clinical stage. She states, “Our belief in ATR 1072's potential to address the root cause of PRKAG2 syndrome is strengthened by our recent findings.”

Future Outlook

Looking ahead, Atrium Therapeutics plans to announce the initial proof-of-concept data from the ongoing clinical trial in the second half of 2027. Additionally, the company aims to file an IND application for its second pipeline candidate, ATR 1086, which targets PLN cardiomyopathy, a progressive cardiac disease caused by mutations in the PLN gene.

Moreover, they remain focused on identifying new development candidates for their rare cardiomyopathy targets in the coming year. Bren Winslow, CFO of Atrium, remarked on the firm’s solid fiscal positioning and strategic initiatives to advance its projects significantly.

About Atrium Therapeutics

Atrium Therapeutics is at the forefront of biopharmaceutical innovation, specializing in RNA therapeutics designed to target and mitigate the effects of genetic cardiomyopathies. The company's proprietary delivery platform combines the benefits of monoclonal antibodies with the precision of oligonucleotides, ensuring focused treatment of heart diseases.

Their ongoing clinical investigations, particularly into PRKAG2 and PLN cardiomyopathies, highlight Atrium's dedication to improving patient outcomes and transforming industry standards in cardiology. As they continue their promising research, the investment community and stakeholders are keen to observe the impact their developments will have on the landscape of genetic heart disease treatments.

For further updates and information, visit Atrium Therapeutics' website.